亦诺微医药港股IPO招股书失效

Core Viewpoint - Immvira Bioscience Inc. has submitted its Hong Kong IPO application, which will expire six months after submission, with Citigroup and CICC as joint sponsors [1] Group 1: Company Overview - Immvira Bioscience Inc. is a biotechnology company focused on clinical demand-driven solutions, aiming to discover, develop, produce, and commercialize novel oncolytic immunotherapies and engineered exosome therapies through proprietary biotechnological methods [2] - The company designs and builds a risk-balanced product portfolio, including oncolytic immunotherapy candidates with best-in-class potential for treating solid tumors and innovative engineered exosome therapeutic products with clinical application prospects or direct commercialization potential [2]